Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

被引：0
|
作者：
Becker, Pamela S.
Estey, Elihu [2 ]
Petersdorf, Stephen
Hendrie, Paul C. [1 ]
Pagel, John M. [2 ]
Stirewalt, Derek
Shustov, Andrei
Storer, Barry E.
Appelbaum, Frederick R. [3 ]
机构：
[1] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1018 / 1018
页数：1
相关论文
共 50 条
  • [1] G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Becker, Pamela S.
    Estey, Elihu
    Petersdorf, Stephen
    Storer, Barry E.
    Appelbaum, Frederick R.
    BLOOD, 2009, 114 (22) : 816 - 816
  • [2] Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
    Becker, Pamela S.
    Kantarjian, Hagop M.
    Appelbaum, Frederick R.
    Petersdorf, Stephen H.
    Storer, Barry
    Pierce, Sherry
    Shan, Jianqin
    Hendrie, Paul C.
    Pagel, John M.
    Shustov, Andrei R.
    Stirewalt, Derek L.
    Faderl, Stephan
    Harrington, Elizabeth
    Estey, Elihu H.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (02) : 182 - 189
  • [3] Limited phase I trial of sequential high dose cytarabine and clofarabine (HiDAC→CLOF) in relapsed or refractory acute myeloid leukemia.
    Powell, Bayard L.
    Lovato, James
    Kimbrough, Claire
    Lyerly, Susan
    Galloway-Daniels, Sonya
    Motley, Cathy
    Harrelson, Robin
    Keung, Yi Kong
    Thakuri, Mohan C.
    Molnar, Istvan
    Levitan, Denise
    Hurd, David Duane
    BLOOD, 2006, 108 (11) : 221B - 221B
  • [4] High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.
    Powell, Bayard
    D'Agostino, Ralph, Jr.
    Levitan, Denise
    Ellis, Leslie Renee
    Lyerly, Susan
    Skiles, Megan
    Manuel, Megan
    Harrelson, Robin
    Kimbrough, Claire
    Hurd, David Duane
    BLOOD, 2008, 112 (11) : 676 - 676
  • [5] Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Becker, Pamela S.
    Smith, Heather A.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Cassaday, Ryan D.
    Gardner, Kelda M.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Anwar, Asma
    Estey, Elihu H.
    Walter, Roland B.
    HAEMATOLOGICA, 2019, 104 (04) : E143 - E146
  • [6] Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
    Becker, Pamela S.
    Medeiros, Bruno C.
    Stein, Anthony Selwyn
    Appelbaum, Frederick R.
    Scott, Bart L.
    Delaney, Colleen
    Othus, Megan
    Hendrie, Paul C.
    Gardner, Kelda M.
    Petersdorf, Stephen
    Pagel, John M.
    Walter, Roland B.
    Parks, Cynthia
    Estey, Elihu H.
    BLOOD, 2012, 120 (21)
  • [7] G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm
    Becker, Pamela S.
    Medeiros, Bruno C.
    Stein, Anthony S.
    Othus, Megan
    Appelbaum, Frederick R.
    Forman, Stephen J.
    Scott, Bart L.
    Hendrie, Paul C.
    Gardner, Kelda M.
    Pagel, John M.
    Walter, Roland B.
    Parks, Cynthia
    Wood, Brent L.
    Abkowitz, Janis L.
    Estey, Elihu H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (04) : 295 - 300
  • [8] Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
    Becker, Pamela S.
    Medeiros, Bruno C.
    Appelbaum, Frederick R.
    Scott, Bart Lee
    Hendrie, Paul C.
    Storer, Barry
    Pierce, Sherry
    Petersdorf, Stephen H.
    Estey, Elihu H.
    BLOOD, 2011, 118 (21) : 1545 - 1545
  • [9] Randomized trial of GM-CSF and G-CSF following high-dose cytarabine and mitoxantrone chemotherapy for relapsed and refractory acute leukemia.
    Baer, Maria R.
    Ford, Laurie A.
    Bundy, Brian N.
    Tighe, Sheila M.
    O'Loughlin, Kieran L.
    Slack, James L.
    Wetzler, Meir
    Wallace, Paul K.
    BLOOD, 2006, 108 (11) : 223B - 223B
  • [10] FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children
    McCarthy, AJ
    Pitcher, LA
    Hann, IM
    Oakhill, A
    MEDICAL AND PEDIATRIC ONCOLOGY, 1999, 32 (06): : 411 - 415
12345